TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Dadiani M, Necula D, Kahana-Edwin S, Oren N, Baram T, Marin I, Morzaev-Sulzbach D, Pavlovski A, Balint-Lahat N, Anafi L, Wiemann S, Korner C, Gal-Yam EN, Avivi C, Kaufman B, Barshack I, Ben-Baruch A.
Dadiani M, et al. Among authors: kaufman b.
Cancer Immunol Immunother. 2020 Jul;69(7):1315-1326. doi: 10.1007/s00262-020-02549-0. Epub 2020 Mar 20.
Cancer Immunol Immunother. 2020.
PMID: 32198536
Free PMC article.